Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) Sees Large Decrease in Short Interest

Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 180,500 shares, a drop of 32.6% from the January 15th total of 267,900 shares. Based on an average daily trading volume, of 138,100 shares, the days-to-cover ratio is currently 1.3 days.

Medexus Pharmaceuticals Price Performance

Shares of OTCMKTS:MEDXF traded down $0.04 during midday trading on Friday, hitting $2.17. The stock had a trading volume of 15,435 shares, compared to its average volume of 52,415. The business’s 50-day simple moving average is $2.48 and its 200-day simple moving average is $2.04. Medexus Pharmaceuticals has a 12 month low of $1.08 and a 12 month high of $3.88.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.